真固生物与亞洲分子診斷實驗室于2021年7月达成战略合作，双方携手共进、优势互补基于Illumina测序平台开发肿瘤诊断应用，联手在香港科技园共建高通量测序创新实验室。
Pillar Biosciences and Asia Molecular Diagnostics Laboratory (“AMDL”) reached a strategic cooperation in July 2021. The two parties will work together and complement each other to develop tumor diagnostic applications based on the Illumina sequencing platform, and jointly build a high-throughput sequencing innovation laboratory in the Hong Kong Science Park.
近期，该实验室满分通过了美国病理学家协会（College of American Pathologists，简称“CAP”）组织的NGSST-B 2021（Next-Generation Sequencing Solid Tumor，实体瘤高通量测序）室间质评，这标志着该实验室在肿瘤高通量测序方面的专业性和数据分析以及解读能力达到了国际先进水准。
Recently, the laboratory has passed the NGSST-B 2021 (Next-Generation Sequencing Solid Tumor, high-throughput sequencing of solid tumors) inter-laboratory quality assessment organized by the College of American Pathologists (“CAP”) with full marks. As a result, the laboratory's proficiencies in high-throughput tumor sequencing, data analysis and interpretations have been recognized to meet with international advanced levels.
（图）CAP NGSST-B 2021检测成绩单
此次的室间质评由亞洲分子診斷實驗室完成实验样本的检测、实验下机后的数据分析、临床注释、报告解读等环节，基因测序采用Illumina的高通量基因测序平台。
In this inter-laboratory quality assessment, AMDL completed the detection of experimental samples, bioinformatics data analysis, clinical annotation and report interpretationwith the use Illumina high-throughput genetic sequencing platform.
（图）Illumina MiSeq Dx基因测序平台
未来，亞洲分子診斷實驗室将基于真固生物提供的测序技术支持，開發基因檢測整體解決方案。在此合作基础之上，双方将继续携手前行，在高通量测序技术的应用、试剂的研发、提升患者满意度等方面不断取得新的成果。双方也将一如既往地保持国际一流水准，以更严格标准要求自身，继续积极参加各类质评考核，精益求精、不断开拓，为医生和患者提供高质量的产品和专业的服务！
In the future, AMDL will develop a total solution for genetic testing based on the sequencing technology support provided by Pillar Biosciences. Based on this cooperation, the two parties will continue to work together to achieve new results in the application of high-throughput sequencing technology, the research and development of reagents, and the improvement of patient satisfaction. Both parties will, as always, maintain a world-class level, require themselves to meet with stricter standards, continue to actively participate in various quality assessments, strive for excellence and continuous development, and provide doctors and patients with high-quality products and professional services!
关于真固生物
About Pillar Biosciences
真固生物是全球屈指可数的拥有基因测序仪自主知识产权和关键核心技术的高科技企业，专注于基因测序产业和试剂的研发制造，从科研到临床，为生命健康守护者提供洞见生命信息的核心工具，赋能基因测序应用场景。真固生物将与合作伙伴一同建设精准医疗生态圈，推动健康产业发展，守护人类生命健康。
Pillar Biosciences is one of the few high-tech companies in the world with independent intellectual property rights and key core technologies of gene sequencing. It focuses on the research & development and manufacture of upstream equipment and reagents in the gene sequencing industry, from scientific research to clinical practice, to shed insights for life and health guardians by making uses of these core tools of life information with enabled gene sequencing application scenarios. Pillar Biosciences will work with partners to build a precision medical ecosystem, promote the development of the health industry, and protect human life and health.
关于亞洲分子診斷實驗室
About Asia Molecular Diagnostics Laboratory
亞洲分子診斷實驗室有限公司是中國生物科技服務控股有限公司(股份代號：8037.HK)的附屬子公司‚专注于肿瘤精准医疗和生物医学大数据技术开发，构建了生物医学知识库和智能化评价模型，为诊疗全过程提供个性化用药基因检测和临床辅助工具，帮助分子靶向、化疗、免疫治疗等药物的用药指导和病情监测；为医疗机构提供肿瘤精准医疗产品和定制化软件开发等服务。
Asia Molecular Diagnostics Laboratory is a subsidiary of China Biotech Services Holdings Limited (Stock code : 8037.HK). AMDL focuses on the development of tumor precision medicine and biomedical big data technology. It is building a biomedical knowledge base and an intelligent evaluation model to provide personalized drug gene detection and clinical auxiliary tools for the whole process of diagnosis and treatment, and help with drug use guidance and disease monitoring of molecular targeting, chemotherapy, immunotherapy and other drugs. It is also providing medical institutions with services such as tumor precision medicine products and customized software development.